PPIDT00484
Drug Information
| Name | Idecabtagene vicleucel |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB16665 |
| Type | biotech |
| Indication | Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an antiCD38 monoclonal antibody.[L32858, L51003, L51539] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Suspension | Intravenous |
300000001
|
| Suspension | Intravenous |
380000000 cells
|
| Suspension | Intravenous |
520000000 cells
|